Close Menu

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Mitomics today announced that it has signed a non-exclusive agreement with LabMD to market its Prostate Core Mitomic Test in the US.

The PCM test is based on mitochondrial DNA and identifies a biomarker that indicates the presence of cancerous cells in prostate biopsy tissue. Thunder Bay, Ontario-based Mitomics said the test has a sensitivity of 84 percent with a negative predictive value of 91 percent.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The first reported coronavirus cases in Europe and the US might not be related to the subsequent outbreaks in those areas, according to the New York Times.

According to NPR, there's a growing shortage of machines to run SARS-CoV-2 tests.

The Wall Street Journal and Kaiser Health News report that antibody testing for SARS-CoV-2 has led to further confusion.

In Nature this week: the largest known collection of human genetic variants, and more.

Jul
15
Sponsored by
LGC SeraCare Life Sciences

Cancer immunotherapy is an exciting new advance for the successful treatment of many forms of metastatic cancer.